### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2022

### ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38942 (Commission File Number)

32-0595345 (I.R.S. Employer Identification No.)

10628 Science Center Drive, Suite 250 San Diego, California 92121 (Address of principal executive offices)

Registrant's telephone number, including area code: (858) 900-2660

#### (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common stock, par value \$0.001 per share	ARCT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

#### Corporate Presentation

On February 17, 2022, the Company posted an updated corporate presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

#### Cautionary Note Regarding Forward-Looking Statements

The presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about: our strategy, future operations, collaborations, the likelihood of success (including safety and efficacy) and promise of our pipeline, the planned initiation, design or completion of clinical trials, anticipated sponsorship and/or funding of clinical trials of our candidates, the likelihood that we will obtain clearance from regulatory authorities to proceed with planned clinical trials, the ability to enroll subjects in clinical trials, the likelihood that preclinical or clinical data will be predictive of future clinical roughts, the pikelihood that clinical trials of any preclinical or clinical studies or regulatory approvals, the potential administration regimen or dosage, or ability to administer multiple doses of, any of our drug candidates, our manufacturing methods and technologies (including purification, lyophilization and stability of our products), the likelihood that a patent will issue from any patent application, our current cash position and adequacy of our capital to support future operations, and any statements of bistorical fact.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions (including the negative thereof) intended to identify forward looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing, and you should not place undue reliance on such forward-looking statements. The forward-looking statements contained or implied in the presentation are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus' most recent Annual Report on Form 10-K with the SEC and in other filings that Arcturus makes with the SEC. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description of Exhibit	
99.1	Presentation dated February 17, 2022	
104	Cover Page to this Current Report on Form 8-K in Inline XBRL	

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.

By:	/s/ Joseph E. Payne
Name:	Joseph E. Payne
Title:	Chief Executive Officer

Date: February 17, 2022




## Forward Looking Statements

This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about: our strategy, future operations, collaborations, the likelihood of success (including safety and efficacy) and promise of our pipeline, the planned initiation, design or completion of clinical trials, anticipated sponsorship and/or funding of clinical trials of our candidates, the likelihood that we will obtain clearance from regulatory authorities to proceed with planned clinical trials, the ability to enroll subjects in clinical trials, the likelihood that preclinical or clinical data will be predictive of future clinical results, the likelihood that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within a particular timeframe, the anticipated timing for regulatory submissions, the timing of, and expectations for, any results of any preclinical or clinical studies or regulatory approvals, the potential administration regimen or dosage, or ability to administer multiple doses of, any of our drug candidates, our manufacturing methods and technologies (including punification, lyophilization and stability of our products), the likelihood that a patent will issue from any patent application, our current cash position and adequacy of our capital to support future operations, and any statements other than statements of historical fact.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions (including the negative thereof) intended to identify forward looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements. The forward-looking statements, and you should not place undue reliance on such forward-looking statements. The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus' most recent Annual Report on Form 10-K with the SEC and in other filings that Arcturus makes with the SEC. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

#### Trademark Attribution


The Arcturus logo and other trademarks of Arcturus appearing in this presentation are the property of Arcturus. All other trademarks, services marks, and trade names in this presentation are the property of their respective owners.





## **Arcturus Therapeutics**





Clinical-Stage mRNA Vaccines and Medicines Company



Publicly Traded (Nasdaq: ARCT)

HQ: San Diego, CA Founded 2013 160+ Employees



### Therapeutic Candidates

LUNAR-COV19	COVID-19 Vaccine		
	(Primary and Booster)		
LUNAR-OTC	Ornithine Transcarbamylas		
	Deficiency		
LUNAR-CF	Cystic Fibrosis		
Additional Earlier Stage Programs			

Multiple Strategic Partners











k



X

## Proprietary mRNA Technologies Driving Therapeutic Programs

## Broad intellectual property portfolio

CHILL HALL	mRNA & STARR™ mRNA		Program	Indication	
GUY (	mRNA Chemistry mRNA Design & Modifications		LUNAR-COV19	COVID-19 Primary and Booster Vaccine	
	mRNA Manufacturing Process		LUNAR-FLU	Flu Vaccine	
ST WE	LUNAR <sup>®</sup> Delivery	$\left<\right>$	LUNAR-OTC	Ornithine Transcarbamylase (OTC) Deficiency	
9880	Formulation Design LUNAR® Drug Product Manufacturing		LUNAR-CF	Cystic Fibrosis	
	230+ Patents & Patent Applications	)	Additional earlier stage programs		



x

## Pipeline of mRNA Therapeutic Candidates

Multiple mRNA therapeutic and vaccine programs in clinical development

Franchise	Candidate	Indication	Prevalence	Route of Administration	Cell Target	Stage	Anticipated Milestones
	LUNAR-COV19 (ARCT-154)	COVID-19 (Targeting VOCs)	Global	Intramuscular	Myocytes & Dendritic Cells	Phase 1/2/3	EUA Filing Commenced Dec 2021 by Vinbiotech; Completion of EUA Submission Q1 2022
Vaccines	LUNAR-COV19 (ARCT-021)	COVID-19	Global	Intramuscular	Myocytes & Dendritic Cells	Phase 2	Phase 3 Initiation (To be Updated by Global Entity)
	LUNAR-FLU	Influenza	Global	Intramuscular	Myocytes & Dendritic Cells	Preclinical	STARR <sup>™</sup> Candidate Selection 2022; CTA 2023
Hepatic	LUNAR-OTC (ARCT-810)	Ornithine Transcarbamylase Deficiency	> 10,000	Intravenous	Periportal Hepatocytes	Phase 2	Interim Data H2 2022
Respiratory	LUNAR-CF (ARCT-032)	Cystic Fibrosis	85,000- 100,000	Inhaled	Bronchial Epithelial Cells	Preclinical	CTA Q3 2022

EUA = Emergency Use Authorization; STARR<sup>TM</sup> = Self-transcribing and replicating RNA, CTA = Clinical Trial Application; ND = Investigational New Drug Application; VOC = Variant of Concern



## Licensed Platforms

Program	Partner	Indication	Stage
LUNAR-GSDIII	ultragenyx	Glycogen Storage Disease Type III	Phase 1/2 *
LUNAR-RARE	ultrageny	Undisclosed Rare Disease	Preclinical
LUNAR-HBV	Johnson-Johnson	Hepatitis B Virus (HBV)	Preclinical
LUNAR-NASH	Takeda	Nonalcoholic Steatohepatitis (NASH)	Preclinical

\* https://clinicaltrials.gov/ct2/show/NCT04574830

\$1B+ in Potential Milestones & Royalties

k

## LUNAR<sup>®</sup> Delivery Technology




## Biodegradable, optimized for targeted cell type





## STARR<sup>™</sup> mRNA Expression Superior to Conventional mRNA

## Self-Transcribing and Replicating mRNA (STARR™) delivered with LUNAR<sup>®</sup> provides increased and longer lasting expression in mouse models



provided enhanced protein expression *in vivo* (mouse)


- LUNAR-COV19 (ARCT-154, ARCT-165, ARCT-021)
  - LUNAR-OTC (ARCT-810)
- LUNAR-CF (ARCT-032

# LUNAR-COV19

Self-Amplifying (STARR<sup>™</sup>) mRNA COVID-19 Primary and Booster Vaccine Candidates

## Arcturus COVID-19 Vaccine Candidates have a Differentiated Profile





x

## Global Manufacturing Footprint



X



Global manufacturing partners include Aldevron, Catalent, Recipharm, Polymun Scientific, ARCALIS, and Vingroup Manufactured GMP finished doses of lyophilized vaccines for stockpiling purposes Global capability to produce millions of doses

- LUNAR-COV19 (ARCT-154, ARCT-165)
- LUNAR-OTC (ARCT-810)
- LUNAR-CF (ARCT-032


## LUNAR-COV19 ARCT-154, ARCT-165

Self-Amplifying (STARR™) mRNA COVID-19 Primary and Booster Vaccine Candidates Targeting



X

## Preclinical Data: ARCT-154 - Neutralizing Antibody Titers in Non-Human Primates



Non-Human primate (NHP) data one month after second dose (7.5 mcg/dose); NHP serum was analyzed using a non-replicating vesicular stomatitis virus pseudo-typed with the spike protein of the SARS-CoV-2 variants of concern indicated. Geometric means were determined from dilution that resulted in 50% inhibition of cells expressing pseudovirus encoded GFP, a surrogate of virus infection. Error bars indicate geometric standard deviation.

## Clinical Trial Update: ARCT-154 and ARCT-165



### ARCT-154 - Phase 1/2/3 Clinical Trial in Vietnam

- Phases 1/2/3 sponsored & funded by Vinbiotech
- · Randomized, observer-blind, placebo-controlled design
- Enrollment completed with over 19,000 participants

Phase	N	Cohorts	Evaluation
1, 2, 3a	100, 300, 600	3:1 ARCT-154 : Placebo	Safety and Immunogenicity
3b	>16,000	1:1 ARCT-154 : Placebo	Safety and Immunogenicity
3c	~2,000	1:1 ARCT-154 : AstraZeneca COVID-19 Vaccine	Head-to-head comparison of immunogenicity non-inferiority

• Participants in Phase 1/2/3a/3b receive two doses of ARCT-154 (5 mcg) or placebo separated by 28 days.

Placebo participants in Phase 1/2/3a/3b receive ARCT-154 (5 mcg) at two months after second dose

Participants in Phase 3c receive two doses of ARCT-154 (5 mcg) or AstraZeneca COVID-19 vaccine separated by 28 days

Emergency Use Authorization (EUA) filing commenced in December 2021; completion anticipated in Q1 2022

### Phase 1/2 Booster Clinical Trial in Singapore and U.S. Evaluating ARCT-021, ARCT-154, and ARCT-165

Two Cohorts (n = 72)

- Cohort A: Primary vaccination evaluation; enrollment ongoing
- · Cohort B: Evaluation of Arcturus vaccine candidates as booster following initial vaccination with Comirnaty®
  - · Data shows encouraging neutralizing antibody activity against variants of concern (including Omicron, Delta, and Beta)

14

Comirnaty® is a trademark of BioNTech

X

Phase 1/2 Booster Clinical Trial Data - Neutralizing Antibodies Against D614G in Validated Pseudovirus Microneutralization Assay

.

1

Days

15

29

10

103

102


101

1

15

29

Pseudovirus Neutralization (AU/ml)



15 29

1

15 29

1

Days

Data from PPD Laboratories, USA

X

ARCTURUS


Boosting with ARCT-154 (n = 12) increased geometric mean neutralizing antibody concentration against D614G 28-fold Boosting with ARCT-165 (n = 12) increased geometric mean neutralizing antibody concentration 24-fold

10<sup>1</sup>



X

### Phase 1/2 Booster Clinical Trial Data – Broad Neutralization Activity Against Variants of Concern upon Boosting with ARCT-154 (5 mcg) in Exploratory Surrogate Virus Neutralization Assay




Boosting with ARCT-154 (n = 12) increased geometric mean neutralizing antibody concentrations against a broad range of Variants of Concern (VoCs) and Variants of Interest (Vols), including Delta and Beta



X


## Booster Clinical Trial Data – Broad Neutralization Activity Against Variants of Concern upon Boosting with ARCT-165 (5 mcg) in Exploratory Surrogate Virus Neutralization Assay



Boosting with ARCT-165 (n = 12) increased geometric mean neutralizing antibody concentrations against a broad range of Variants of Concern (VoCs) and Variants of Interest (VoIs), including Delta and Beta



Phase 1/2 Booster Clinical Trial Data – Neutralizing Antibodies Against Omicron in Exploratory Microneutralization Assay



Data from Penny Moore Lab, South Africa

X

Boosting with ARCT-154 (n = 12) increased geometric mean neutralizing antibody titers against Omicron **54-fold** Boosting with ARCT-165 (n = 12) increased geometric mean neutralizing antibody titers **47-fold** 


- LUNAR-COV19 (ARCT-154, ARCT-165, ARCT-021)
- LUNAR-OTC (ARCT-810)
- LUNAR-CF (ARCT-032)

## LUNAR-COV19 ARCT-021

STARR<sup>™</sup> COVID-19 mRNA Vaccine Candidate

## STARR<sup>™</sup> Preclinical Data Using Ancestral/Wuhan Strain – Robust Immune Response in Mouse Models






• Single administration with a very low dose of Arcturus COVID vaccine resulted in potent immune reaction against ancestral/Wuhan strain

STARR™ mRNA generate neutralizing antibodies (anti-SARS-CoV-2 Spike Glycoprotein IgG) and a cellular T-cell mediated immune response at a much lower dose level compared to conventional mRNA

k



## ARCT-021 Activity Against Ancestral/Wuhan Strain in Challenge Models



## ARCT-021 Clinical Trials

### Phase 1/2 Clinical Trial

- · Completed dosing all subjects (n=106), including older adults
- High seroconversion rates for IgG binding antibodies, and Th1 dominant CD4+ immune responses, neutralizing antibodies (PRNT50) Geometric Mean Titer (GMT) levels in the range of titers observed in convalescent serum
- · Favorable safety and tolerability; no subjects withdrawn from dosing


### Phase 2 Clinical Trial Ongoing


- · Fully enrolled with 579 participants dosed across USA and Singapore
- Two dose levels evaluated: 5 mcg and 7.5 mcg
- Two interim analysis conducted; DSMB recommended to proceed with no modifications to protocol
- >90% seroconversion after single 5 mcg dose for IgG antibodies binding SARS-CoV-2 spike protein
- Booster vaccination with ARCT-021, -154, and -165 also being evaluated

### Phase 3 Clinical Trial Initiation Anticipated

- Global entity to sponsor and fund
- Multinational study
- Placebo-controlled
- To enroll tens of thousands of participants
- 5 mcg, single injection regimen


Comirnaty® is a trademark of BioNTech





A ARCTURUS

## Ornithine Transcarbamylase (OTC) Deficiency: ARCT-810 Market Opportunity



## LUNAR-OTC



### Exceeds target of 10% enzyme replacement at low, medium, and high doses in OTC-deficient mouse model

- OTCD impacts ureagenesis (ammonia detoxification)
- The main site of ureagenesis is the periportal region of the liver\*

#### Periportal Expression in the Liver of OTC Protein 110-100-. . . . . % Natural Levels 90-80-70-60-50-40-30-20 ···· 10% OTC Activity Threshold 10 0 Mid High Low Dose Level

\*Li, L. et al. PGC-1a Promotes Ureagenesis in Mouse Periportal Hepatocytes through SIRT3 and SIRT5 in Response to Glucagon. Scientific Reports. 6:24156 | DOI: 10.1038/srep24156, April 2016 \*Lamers, W.H., Hakvoort, T.B.M., and Köhler, E.S. 'Molecular Pathology of Liver Diseases' in Monga S.P.S. (ed.), MOLECULAR PATHOLOGY LIBRARY SERIES, Springer Publishing, New York, pp. 125-132 | DOI: 10.1007/978-1-4419-7107-4

LUNAR-OTC treatment increases OTC expression in mouse periportal hepatocytes (main site of ureagenesis)

## ARCT-810 Clinical Update



### Phase 1 Clinical Trial in Health Volunteers Completed

- · Single doses of ARCT-810 (OTC mRNA) up to 0.4 mg/kg found to be generally safe and well tolerated
- All doses tested were in the expected therapeutic range

### Phase 1b Clinical Trial in OTC-Deficiency Adults Ongoing

- · Multiple sites activated or in start-up
- Anticipate completion of first dose cohort in 2Q 2022

## Phase 2 Clinical Trial in OTC-Deficient Adolescents and Adults Approved to Proceed


Randomized, double-blind, placebo-controlled, nested single and multiple ascending dose

Enroll up to 24 subjects across two dose cohorts; Approved to proceed in multiple European countries

- Primary Endpoints
  Safety and tolerability
- Secondary Endpoints
  Pharmacokinetics and pharmacodynamic measures (ureagenesis assay, 24-hr ammonia profile)
- Exploratory Endpoints
  Biomarket

Biomarkers include plasma amino acids, plasma OTC enzyme activity, and urine orotic acid levels

Interim Phase 2 data anticipated in H2 2022 in a subset of participants



## Cystic Fibrosis: ARCT-032 Market Opportunity

## ARCTURUS



### **Cystic Fibrosis**

85,000-100,000 worldwide prevalence

Caused by genetic mutations in the CFTR gene, resulting in aberrant flux of ions in and out of cells, causing thick mucus buildup in lung airways

Chronic airway obstruction leads to infection and inflammation, which causes permanent tissue scarring and respiratory failure



### **Unmet Medical Need**

CFTR functional modulators are not approved for treatment of all patients

Present standard of care does not effectively prevent long-term effects of mucus accumulation. CF patients with late-stage loss of respiratory function require lung transplant



### LUNAR-CF Aims to Restore CFTR Function

An mRNA replacement therapy has the potential to deliver a new copy of CFTR into the lungs of CF patients, independent of any genotype


A functional CFTR protein can restore chloride channel efflux in the airways, reducing mucus accumulation, tissue scarring and minimizing the progressive respiratory dysfunction observed in CF patients

### CTA filing for First-in-Human study planned Q3 2022




## Aerosolized LUNAR® Delivery Platform for Lung





- Aerosolized LUNAR®-mRNA is within the appropriate droplet size and maintains expression
- ARCT-032 improves CFTR activity in CF mouse model

# LUNAR<sup>®</sup>-mRNA Delivery to Airways Epithelium Transduction demonstrated by brown and green staining



LUNAR® delivery is maintained across rodent and nonrodents species

X


A ARCTURUS

## Functional Restoration of Chloride Current with ARCT-032



### CFTR-deficient (G551D) Ferret Bronchial Epithelial Cells





Dose-dependent restoration of chloride activity in ferret bronchial epithelial cells carrying a G551D mutation

Dose-dependent restoration of chloride activity with ARCT-032 Activity comparable to VX-770 (ivacaftor) in G551D gating-mutation cells

# Restoration of CFTR Expression and Function in Human bronchial epithelial cells with F508del mutation


ARCT-032 restored chloride activity in ALI

culture of HBE cells carrying a F508del<sup>+/+</sup>

mutation



Increased C/B band ratio in F508del\*/+ HBE cells transduced with ARCT-032



High levels of mature CFTR protein were

generated in F508del<sup>+/+</sup> HBE cells transduced

with ARCT-032

ARCT-032 resulted in a dose-dependent restoration of chloride activity and generation of high levels of mature C-Band CFTR in F508del<sup>+/+</sup> human bronchial epithelial cells



# Anticipated Near-Term Milestones



ARCT-154 (COVID vaccine candidate targeting VOCs)				
EUA Filing in Vietnam	Completion of Submission Q1 2022			
ARCT-154 (COVID vaccine candidate targeting VOCs)				
Clarity on Regulatory Path for Boos	ter Indication Q1 2022			
ARCT-021 (COVID vaccine candida	ate)			
Phase 3 Initiation	To be Updated by Global Entity			
ARCT-810(LUNAR-OTC)				
Interim Phase 2 Data	H2 2022			
ARCT-032(LUNAR-CF)				
Clinical Trial Application	Q3 2022			
LUNAR-FLU				
Clinical Trial Application	STARR™ Candidate Selection 2022; CTA 2023			

34

A ARCTURUS



### **Team Arcturus**

#### **Management Team**



President & CEO



Joseph E. Payne, MSc Pad Chivukula, Ph.D. Andrew Sassine, MBA

CSO & COO



CFO

**Fidelity** 





Chief Legal Officer

Μ

MINTZ



Lance Kurata, J.D. Dushyant Varshney, Ph.D.



CTO

**Pfizer** 





Steve Hughes, M.D. Strategic Clinical Advisor





















Kelly Lindert, M.D.

CDO, Vaccines





# **Board of Directors**













Andrew Sassine, MBA Joseph E. Payne, MSc

Director of the Board, CFO

Pidelity

Director of the Board XX Krystal

Jing L. Marantz, M.D., Ph.D., MBA

x



ResMed

đ

1

Edward W. Holmes, M.D. Director of the Board



**CALTHEA** 

35

Magda Marquet, Ph.D. Director of the Board

Director of the Board President & CEO

MERCK

Director of the Board

James Barlow, MA 📢 Allergan

Sanford Consortium





### **Team Arcturus**

# ARCTURUS

### Scientific Advisory Board







37





### LUNAR-COV19 Seroconversion Data against Ancestral/Wuhan Strain (Preclinical)

### Seroconversion rate (% of Animals) – STARR™ mRNA vs. conventional mRNA


Single Dose (mcg)	LUNAR <sup>®</sup> Delivery				
	STARR™	STARR™ mRNA (%)		Conventional mRNA (%)	
	Day 10	Day 19	Day 10	Day 19	
0.2	40	60	20	20	
2	80	100	20	0	
10	100	100	40	80	

100% of mice seroconverted by day 19 at a single low dose (2 mcg)



### Preclinical Data: Anti-Spike Protein Levels Continue to Increase up to 50 Days

Single administration of LUNAR-COV19 ancestral/Wuhan strain spike protein mRNA in conventional mRNA or STARR<sup>™</sup> format (in mice)




- Higher titers (anti-SARS-CoV-2 Spike Glycoprotein IgG) elicited by STARR™ mRNA
- Titers continue to increase up to 50 days with STARR™ mRNA; plateau reached with conventional mRNA
- Dose dependent increase in IgG titers; Luminex bead assay, 1/2000 serum dilution

### Preclinical Data: Neutralizing Antibodies Continue to Increase for 60 Days

Single administration (small dose, 2 mcg) of LUNAR-COV19 ancestral/Wuhan strain spike protein (mouse)

ARCTURUS

X




After single dose (2 mcg) of LUNAR-COV19, neutralizing antibodies continue to increase for 60 days (>300 titer)

41



k

### Preclinical Data: Arcturus Vaccine Elicits a Dose-Dependent Cell-Mediated Immune Response against Ancestral/Wuhan strain in Mouse Model




- RNA dose-dependent increase in IFN-γ positive CD8+ T-cells
- Th1 biased CD4+ response and stable Th1/Th2 ratio with increased RNA dose indicate balanced cell mediated immune response



X

### ATX Lipids Facilitate Delivery and are Biodegradable




#### Next generation ATX lipids retain degradability and improve delivery efficiency

13



### ATX 2.0 Lipid is Biodegradable and Exhibits a Favorable PK/PD Profile



- ATX Lipid (the major component in LUNAR® technology) is degraded in vivo
- ATX 2.0 Lipid half-life in the liver is approximately 20 hours

K

### Key Existing Country Relationships



### Singapore

**Medical School** 

DukeNUS Research Partnership with **Duke-NUS Medical School** 



Financial Support from the **Economic Development** Board of Singapore

- \$10M Grant for Research and Preclinical Work .
- \$6.7M Grant for Phase 1/2 Clinical Trial .
- Executed Manufacturing Support Agreement .
- for \$46.6M Non-Recourse Loan .
- . Up to \$175M in vaccine purchases

#### Vietnam



Israel

#### Collaboration with Vingroup

- Fully Sponsored Phase 1/2/3 Trial of ARCT-154 Establish Hanoi Manufacturing Facility .
- (Up to 200M doses/year) \$40M Upfront Payment and Potential Royalties
- Based on Vaccines Produced



#### Supply Agreement with Israel Ministry of Health


- Announced August 18, 2020 .
- . \$12.5 M Initial Reserve Payment was paid in October 2020

45




X

### Drug Substance: mRNA Design



Sustained hEPO activity in NHPs upon repeat dosing


Weekly Dosing in Non-Human Primates (NHPs)



#### Proprietary mRNA optimization platform demonstrates sustained activity upon repeat dosing in NHPs



### Drug Substance (mRNA) Manufacturing





47

ARCTURUS



### Drug Substance (mRNA) Manufacturing





GMP Lots Produced at CMO as part of recent GMP campaign

Several successful GMP campaigns; acceptable quality and yield